|1.||Guerrieri-Gonzaga, Aliana: 2 articles (07/2012 - 04/2004)|
|2.||Decensi, Andrea: 2 articles (07/2012 - 04/2004)|
|3.||Gjerde, Jennifer: 2 articles (07/2012 - 04/2004)|
|4.||Lien, Ernst A: 2 articles (07/2012 - 04/2004)|
|5.||Kester, Mark: 1 article (07/2015)|
|6.||Barth, Brian M: 1 article (07/2015)|
|7.||Claxton, David F: 1 article (07/2015)|
|8.||Tan, Su-Fern: 1 article (07/2015)|
|9.||Morad, Samy A F: 1 article (07/2015)|
|10.||Cabot, Myles C: 1 article (07/2015)|
01/01/1988 - "Studies with 4-hydroxytamoxifen and N-desmethyltamoxifen (the principal metabolites in patients) showed that each was effective in inhibiting estradiol-stimulated tumor growth. "
06/15/1988 - "The human mammary cancer cell line MCF-7 in culture was used to study the effect of tamoxifen and its derivatives: 4-hydroxytamoxifen (4-OH-Tam), N-desmethyltamoxifen (Dem-Tam) and cis-tamoxifen (cis-Tam) on the uptake and conversion of [3H]estrone sulfate (3H-E1S) to estradiol (E2). "
08/01/2001 - "Since the contribution of these alpha-hydroxy metabolites of tamoxifen to the induction of endometrial tumors is presently unknown, we compared the extent of DNA adduct formation in liver and selected non-hepatic tissues of female Sprague-Dawley rats treated by gavage with tamoxifen, alpha-hydroxytamoxifen, N-desmethyltamoxifen, alpha-hydroxy-N-desmethyltamoxifen and N,N-didesmethyltamoxifen, or intraperitoneal injection with tamoxifen, alpha-hydroxytamoxifen, 3-hydroxytamoxifen and 4-hydroxytamoxifen. "
|2.||Breast Neoplasms (Breast Cancer)
08/01/1983 - "N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro."
09/01/2013 - "Moreover, PpIX + βCD effectively solubilized the breast cancer drug tamoxifen metabolite N-desmethyltamoxifen (NDMTAM) in water. "
12/01/1993 - "Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer."
01/01/1990 - "Serum concentrations of tamoxifen, 4-OH-tamoxifen, N-desmethyltamoxifen, and metabolites E and Y were assayed to assess the variation of tamoxifen-metabolism during short-term and long-term endocrine treatment for breast cancer. "
01/01/1980 - "Serum concentrations of tamoxifen and its metabolite, N-desmethyltamoxifen (DMT) were determined in six post-menopausal patients with advanced breast cancer. "
|3.||Astrocytoma (Pilocytic Astrocytoma)
07/01/1994 - "Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines."
10/01/1995 - "Tamoxifen and its main metabolite N-desmethyltamoxifen (NDMTmx) have been shown to increase intracellular daunorubicin (DNR) levels in human leukemia cell lines that display the multidrug resistant (MDR) phenotype. "
12/01/1993 - "We investigated the intra-tumoural disposition of tamoxifen (TAM) and its major metabolite N-desmethyltamoxifen (DMT) in 36 human breast carcinomas following short-term therapy. "
01/01/1986 - "We examined the direct effect of progesterone, medroxyprogesteroneacetate, gestoneron, 17-beta-estradiol, tamoxifen, 4-OH-tamoxifen, or N-desmethyltamoxifen on the proliferative capacity of ovarian carcinoma cells by means of the colony assay described by Hamburger and Salmon. "
|10.||estrone sulfate (Evex)